



# Pharma Finance 2007

## ROMA - ITALY - MAY 10-11

# 5TH ANNUAL PARTNERING CONFERENCE

### Market Data (AS OF MAY 1, 2007)



Symbol	REX
Exchange	AMEX
Current Price	\$1.04
Shares Outstanding	72.8M
Market Capital	\$75.5M
52wk RANGE	\$0.75-\$1.73
Average Volume	19,744
YTD % Change	~0%

### COMPANY FACT SHEET



**ViRexx Medical Corp.**  
 8223 Roper Road NW  
 Edmonton, Alberta, Canada  
 T6E 6S4  
 (780) 433-4411

[www.virexx.com](http://www.virexx.com)



**Dr. Lorne Tyrrell**  
 CEO and CSO

### FINANCIAL HIGHLIGHTS (YEAR ENDING DEC 31ST, 2006)

<b>Net Revenue:</b>	<b>N/A</b>	<b>Earnings per Share:</b>	<b>(0.22)</b>
<b>Net Income:</b>	<b>(15.46M)</b>	<b>Weighted Average:</b>	<b>N/A</b>

### CONFERENCE OBJECTIVES

Partnering and Licensing opportunities.

### RECENT DEVELOPMENTS

**April 9, 2007**  
 ViRexx Announces Change in Board and Termination of Public Financing

**November 28, 2006**  
 ViRexx to Focus on Near Term Potential Revenue Streams

**November 15, 2006**  
 ViRexx Founders Inducted Into the BioIndustry Hall of Fame

**November 6, 2006**  
 ViRexx Announces Comprehensive Partnership for OvaRex'R' Mab

### PRODUCT AND PRODUCT CANDIDATE PIPELINE



ViRexx's business strategy is to develop and commercialize therapeutic products originating from the Company's AIT™, Chimigen™ & T-ACT™ platform technologies in a timely and effective manner. The Company will realize value by focusing on commercializing unique, patent-protected and patent-pending products through pharmaceutical company partnerships and alliances. In order to build value for strategic partnering, ViRexx will aggressively pursue regulatory approval of products by conducting additional research and directing pre-clinical and Phase I and II clinical trials.

### Company Description

ViRexx is an Edmonton, Alberta-based biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and chronic viral infections. ViRexx's most advanced clinical programs include drug candidates for the treatment of ovarian cancer, chronic Hepatitis B & C and solid tumors.